| Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. | |
| | |
MedLine Citation:
|
PMID: 23322234 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
AIB1 (amplified in breast cancer 1) is an estrogen receptorα (ERα) co-activator, known to be amplified and overexpressed in a fraction of breast cancers. It has been linked to prognosis and tamoxifen resistance. However, results have been ambiguous. The different functions of AIB1 in ERα-positive and -negative disease are poorly understood. Therefore, we analyzed the clinical significance of AIB1 in breast cancer with respect to ERα-status and characterized the subgroups. 2,197 breast carcinomas sampled on a pre-existing tissue microarray (TMA) were analyzed for AIB1 expression and amplification by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Results: AIB1 expression was detected in 60 % of the tumors. It was associated with tumor size (p = 0.003), high histological grade (p < 0.0001), poor disease-specific, and overall survival (p = 0.0018 and p = 0.003). There was a strong inverse relationship between AIB1 and ERα expression (p < 0.0001). AIB1 overexpression was associated with increased Ki67 labeling index (p < 0.0001), even if analyzed for different ER expression levels. AIB1 amplification was found in 11 % of the carcinomas. It was associated with high histological grade (p = 0.0012), lymph node involvement (p = 0.0163), and poor disease-specific survival (p = 0.0032) but not with overall survival (p = 0.1672) or ER status (p = 0.4456). If ER-positive tumors were stratified according to their AIB1 amplification status, there was a significant worse disease-specific survival in cases showing AIB1 amplification (p = 0.0017). AIB1 expression is associated with unfavorable prognosis and tumor phenotype. It seems to unfold its oncogenic potential at least in part independent from its role as an ERα co-activator. AIB1 has an impact on cell cycle regulation in ERα-positive as well as ERα-negative tumors. Furthermore, AIB1 amplification characterizes a subgroup of ERα-positive breast cancer with worse outcome. Therefore, AIB1 might be helpful to identify those ERα-positive breast cancers patients who are candidates for adjuvant chemotherapy. |
| | |
Authors:
|
E Burandt; G Jens; F Holst; F Jänicke; V Müller; A Quaas; M Choschzick; W Wilczak; L Terracciano; R Simon; G Sauter; A Lebeau |
Related Documents
:
|
18323284 - Fine needle aspiration cytology of mammary carcinoma with choriocarcinomatous features:... 196464 - Studies on cytologic characteristics of mammary aspiration smears based on histologic t... 8807244 - Fine-needle aspiration cytology of metastatic ovarian carcinoma to the breast. 20931514 - Diagnostic accuracy of fine needle aspiration cytology of palpable breast masses in ben... 1948604 - Treatment of carcinoma of the breast in the older geriatric patient. 23244094 - Risk factors of breast cancer among women in eastern india: a tertiary hospital based c... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-16 |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: - ISSN: 1573-7217 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany, e.burandt@uke.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate...
Next Document: Direct-to-consumer genomic testing from the perspective of the health professional: a systematic rev...